Alzheimer’s disease (AD) is an age-related neurodegenerative disease that is clinically characterized by progressive cognitive decline. Glucagon-like peptide-1 (GLP-1) is a hormone that belongs to the incretin family and is released in response to nutrient intake. It plays a role in maintaining metabolic homeostasis and has been suggested to be involved in maintaining the brain microenvironment. However, the role of GLP-1 in AD pathogenesis has not been fully illustrated.
Objective:
This study aims to investigate the clinical relevance of GLP-1 in AD and the effects of GLP-1 in amyloid-β (Aβ) metabolism in vitro.
Methods:
In this study, 39 AD patients and 120 cognitively intact controls were included. Plasma levels of GLP-1 were measured using ELISA. SH-SY5Y cells overexpressing human amyloid precursor protein (APP) were treated with GLP-1. Western blot analysis was used to assess the effects of GLP-1 on the metabolism of Aβ.
Results:
Plasma GLP-1 levels were decreased with aging. Plasma GLP-1 levels were lower in AD patients in comparison with healthy older adults. Plasma GLP-1 levels were positively associated with Mini-Mental State Examination scores but negatively associated with plasma pTau181 levels. GLP-1 dose-dependently increased the area fraction of mitochondrial staining in vitro. Furthermore, GLP-1 dose-dependently promoted the α-cleavage of APP, thus reducing the generation of Aβ.
Conclusions:
GLP-1 has neuroprotective effects in AD, and therefore the decrease in GLP-1 levels during aging might contribute to the development of AD.
NicholsE, SteinmetzJD, VollsetSE, FukutakiK, ChalekJ, Abd-AllahF, AbdoliA, AbualhasanA, Abu-GharbiehE, AkramTT, et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health7, e105–e125.
2.
MattsonMP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev77, 1081–1132.
3.
TaylorHA, PrzemylskaL, ClavaneEM, MeakinPJ (2022) BACE1: More than just a β-secretase. Obes Rev23, e13430.
4.
HurJ-Y (2022)
γ-secretase in Alzheimer’s disease. ExpMol Med54, 433–446.
5.
MancinettiF, XenosD, De FanoM, MazzieriA, PorcellatiF, BoccardiV, MecocciP (2023) Diabetes-Alzheimer’s connection in older age: SGLT2 inhibitors as promising modulators of disease pathways. Ageing Res Rev90, 102018.
6.
AmidfarM, AskariG, KimY-K (2024) Association of metabolic dysfunction with cognitive decline and Alzheimer’s disease: A review of metabolomic evidence. Prog Neuropsychopharmacol Biol Psychiatry128, 110848.
7.
HolstJJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev87, 1409–1439.
8.
ViljoenA, BainSC (2023) Glucagon-like peptide 1 therapy: From discovery to type 2 diabetes and beyond. Endocrinol Metab38, 25–33.
9.
TrappS, BrierleyDI (2022) Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br J Pharmacol179, 557–570.
10.
HölscherC (2022) Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol179, 695–714.
11.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
12.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJQ, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR, STAR-Band BBBIG working groups (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
13.
LiY, GlotfeltyEJ, KarlssonT, FortunoLV, HarveyBK, GreigNH (2021) The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. J Neurochem159, 867–886.
14.
LiY, LuJ, HouY, HuangS, PeiG (2022) Alzheimer’s amyloid-β accelerates human neuronal cell senescence which could be rescued by sirtuin-1 and aspirin. Front Cell Neurosci16, 906270.
15.
LiuL, YuZ, ChenJ, LiuB, WuC, LiY, XuJ, LiP (2023) Lucialdehyde B suppresses proliferation and induces mitochondria-dependent apoptosis in nasopharyngeal carcinoma CNE2 cells. Pharm Biol61, 918–926.
16.
PengW, ZhouR, SunZ-F, LongJ-W, GongY-Q (2022) Novel insights into the roles and mechanisms of GLP-1 receptor agonists against aging-related diseases. Aging Dis13, 468–490.
17.
MielkeMM, FrankRD, DageJL, JerominA, AshtonNJ, BlennowK, KarikariTK, VanmechelenE, ZetterbergH, Algeciras-SchimnichA, KnopmanDS, LoweV, BuG, VemuriP, Graff-RadfordJ, JackCR, PetersenRC (2021) Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol78, 1108.
18.
TzartosJS, BoufidouF, StergiouC, KuhleJ, WillemseE, PalaiodimouL, TsantzaliI, SideriE, BonakisA, GiannopoulosS, VoumvourakisKI, TsivgoulisG, TzartosSJ, KapakiE, ParaskevasGP (2022) Plasma P-Tau181 for the discrimination of Alzheimer’s disease from other primary dementing and/or movement disorders. Biomolecules12, 1099.
19.
MoraisLH, SchreiberHL, MazmanianSK (2021) The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol19, 241–255.
20.
AngelucciF, CechovaK, AmlerovaJ, HortJ (2019) Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation16, 108.
BakerDJ, PetersenRCCellular senescence in brain aging and neurodegenerative diseases: Evidence and perspectives. J Clin Invest128, 1208–1216.
23.
NowellJ, BluntE, GuptaD, EdisonP (2023) Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Res Rev89, 101979.
24.
ColinIM, SzczepanskiLW, GérardA-C, ElosegiJ-A (2023) Emerging evidence for the use of antidiabetic drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer’s disease. touchREV Endocrinol19, 16–24.
25.
FuJ, QiuW, ZhengH, QiC, HuS, WuW, WangH, WuG, CaoP, MaZ, ZhengC, MaW-J, ZhouH-W, HeY (2023) Ageing trajectory of the gut microbiota is associated with metabolic diseases in a chronological age-dependent manner. Gut72, 1431–1433.
KellarD, CraftS (2020) Brain insulin resistance in Alzheimer’s disease and related disorders: Mechanisms and therapeutic approaches. Lancet Neurol19, 758–766.
28.
MorínigoR, MoizéV, MusriM, LacyAM, NavarroS, MarínJL, DelgadoS, CasamitjanaR, VidalJ (2006) Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab91, 1735–1740.
29.
DruckerDJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab57, 101351.
30.
BullerS, BlouetC (2024) Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss. Am J Physiol Endocrinol Metab326, E472–E480.
31.
GuptaT, KaurM, ShekhawatD, AggarwalR, NandaN, SahniD (2023) IInvestigating the glucagon-like peptide-1
and its receptor in human brain: Distribution of expression, functional implications, age-related changes and species specific characteristics. Basic Clin Neurosci14, 341–354
32.
QinZ, SunZ, HuangJ, HuY, WuZ, MeiB (2008) Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett444, 217–221.
33.
LiY, DuffyKB, OttingerMA, RayB, BaileyJA, HollowayHW, TweedieD, PerryT, MattsonMP, KapogiannisD, SambamurtiK, LahiriDK, GreigNH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis19, 1205–1219.
34.
PerryT, LahiriDK, SambamurtiK, ChenD, MattsonMP, EganJM, GreigNH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res72, 603–612.
35.
ZagoAM, CarvalhoFB, RahmeierFL, SantinM, GuimarãesGR, GutierresJM, DaC., FernandesM (2023) Exendin- 4 prevents memory loss and neuronal death in rats with sporadic Alzheimer-like disease. Mol Neurobiol, doi: 10.1007/s12035-023-03698-w.
36.
KimuraR, OkouchiM, FujiokaH, IchiyanagiA, RyugeF, MizunoT, ImaedaK, OkayamaN, KamiyaY, AsaiK, JohT (2009) Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience162, 1212–1219.
37.
ReichN, HölscherC (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci16, 970925.
38.
EncinasM, IglesiasM, LiuY, WangH, MuhaisenA, CeñaV, GallegoC, ComellaJX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem75, 991–1003.
39.
ChowH-M, ShiM, ChengA, GaoY, ChenG, SongX, SoRWL, ZhangJ, HerrupK (2019) Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat Neurosci22, 1806–1819.
KreinerFF, von ScholtenBJ, KurtzhalsP, GoughSCL (2023) Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. Aging Cell22, e13818.
